Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

被引：0

作者：

Bobin, Arthur ^{[1
]}

Hulin, Cyrille ^{[2
]}

Lambert, Jerome ^{[3
]}

Perrot, Aurore ^{[4
]}

Manier, Salomon ^{[5
]}

Montes, Lydia ^{[6
]}

Jaccard, Arnaud ^{[7
]}

Karlin, Lionel ^{[8
]}

Godmer, Pascal ^{[9
]}

Caillot, Denis ^{[10
,11
]}

Chalopin, Thomas ^{[12
]}

Roul, Christophe ^{[13
]}

Mariette, Clara ^{[14
]}

Rigaudeau, Sophie ^{[15
]}

Delaunay, Jacques ^{[16
]}

Dingremont, Claire ^{[17
]}

Santagostino, Alberto ^{[18
]}

Dib, Mamoun ^{[19
]}

Macro, Margaret ^{[20
]}

Tiab, Mourad ^{[21
]}

Laribi, Kamel ^{[22
]}

Petit, Emmanuelle Bourgeois ^{[23
]}

Calmettes, Claire ^{[24
]}

Piocelle, Frederique Orsini ^{[25
]}

Bareau, Benoit ^{[26
]}

Tabrizi, Reza ^{[27
]}

Vincent, Laure ^{[28
]}

Mohty, Mohamad ^{[29
]}

Touzeau, Cyrille ^{[30
]}

Corre, Jill ^{[31
]}

Moreau, Philippe ^{[32
]}

Facon, Thierry ^{[33
]}

Loiseau, Herve Avet ^{[34
]}

Leleu, Xavier ^{[35
,36
]}

机构：

[1] CHU Poitiers, Poitiers, France

[2] Ctr Hosp Univ Bordeaux, Pessac, France

[3] Univ Paris Cite, St Louis Univ Hosp, AP HP, Biostat & Med Informat Dept, Paris, France

[4] Inst Univ Canc Toulouse Oncopole, Serv Hematol, Toulouse, France

[5] Ctr Hosp Univ Hop Huriez, Lille, France

[6] Ctr Hosp Univ Amiens Picardie, Serv Hematol Clin, Amiens, France

[7] CHU Limoges, Hematol Clin, Hop Dupuytren, Limoges 1, France

[8] Hosp Civils Lyon, Hop Lyon Sud, Pierre Benite, France

[9] CH Vannes, Vannes, France

[10] Univ Burgundy & France Comte, Univ Hosp INSERM UMR1231, Dijon, France

[11] Univ Burgundy & France Comte, SAPHIIR UMR 1231, Dijon, France

[12] Ctr Hosp Univ Tours, Tours, France

[13] CH La Rochelle, La Rochelle, France

[14] CHU Grenoble, Grenoble, France

[15] CH Versailles, Le Chesnay Rocquencourt, France

[16] Ctr Hosp Univ Nantes, Nantes, France

[17] Ch Tarbes, Tarbes, France

[18] CH Troyes, Troyes, France

[19] CHU Angers, Angers, France

[20] Hop Cote De Nacre, Caen, France

[21] Ctr Hosp Dept, La Roche Sur Yon 9, France

[22] Le Mans Hosp, Hematol Dept, Le Mans, France

[23] CHU Lille, Lille, France

[24] CH Perigueux, Perigueux, France

[25] CH Metz, Metz Tessy, France

[26] Cabinet Med, Rennes, France

[27] CH Mont de Marsan, Mont De Marsan, France

[28] Montpellier Univ, Hosp Ctr, Dept Clin Hematol, Montpellier, France

[29] Hop St Antoine, Paris, France

[30] Ctr Hosp Univ Nantes, Nantes, France

[31] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[32] Univ Hosp Hotel Dieu, Nantes, France

[33] Lille Univ Hosp, Dept Haematol, Lille, France

[34] Univ Hosp Toulouse, IUCT Oncopole, Unite Genom Myelome, Toulouse, France

[35] Serv Hematol & Therapie Cellulaire, Poitiers, France

[36] Univ Poitiers Hosp, INSERM CIC 1042, Poitiers, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185699

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
Ocio, Enrique M.
Rodriguez Otero, Paula
Bringhen, Sara
Oliva, Stefania
Nogai, Axel
Attal, Michel
Moreau, Philippe
Kanagavel, Dheepak
Fitzmaurice, Thomas F.
Wu, Junlong
Martinez Lopez, Joaquin
BLOOD, 2018, 132
[22] Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vassiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S103 - S103
[23] Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
Kumar, Shaji K.
Facon, Thierry
Usmani, Saad Z.
Plesner, Torben
Orlowski, Robert Z.
Touzeau, Cyrille
Basu, Supratik
Bahlis, Nizar J.
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Christopher P.
Weisel, Katja
Hulin, Cyrille
Karlin, Lionel
Preis, Meir
Broyl, Annemiek
Renwick, William
Hansson, Markus
Krevvata, Maria
Wang, Jianping
Van Rampelbergh, Rian
Ukropec, Jon
Uhlar, Clarissa M.
Kobos, Rachel
Perrot, Aurore
BLOOD, 2020, 136
[24] Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Lin, Tung-Liang
Chim, Chor Sang
Qi, Ming
Wang, Jianping
Lu, Xiaolin
Song, Yang
Jia, Bin
Yang, Xue
Liu, Wenyu
Zhou, Tianyuan
Yin, Lu
Li, Yunan
Zhang, Renyi
Hou, Jian
Wang, Jianxiang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (06): : 446 - +
[25] Randomised, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone Followed by Ciltacabtagene Autoleucel Versus Bortezomib, Lenalidomide and Dexamethasone Followed by Lenalidomide and Dexamethasone Maintenance in Patients With Newly Diagnosed Multiple Myeloma Not Intended for Transplant: CARTITUDE-5
Dytfeld, Dominik
Dhakal, Binod
Agha, Mounzer
Manier, Salomon
Delforge, Michel
Kuppens, Steven
Afifi, Salma
Deraedt, William
Taraseviciute-Morris, Agne
Schecter, Jordan M.
Gilbert, Jane
Yalniz, Fevzi
Florendo, Erika
Pacaud, Lida
Hungria, Vania
Usmani, Saad Z.
Mateos, Maria-Victoria
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 122 - 123
[26] Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study
Harousseau, Jean-Luc
Attal, Michel
Leleu, Xavier
Troncy, Jacques
Pegourie, Brigitte
Stoppa, Anne-Marie
Hulin, Cyrille
Benboubker, Lofti
Fuzibet, Jean-Gabriel
Renaud, Marc
Moreau, Philippe
Avet-Loiseau, Herve
HAEMATOLOGICA, 2006, 91 (11) : 1498 - 1505
[27] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar, Shaji K.
Moreau, Philippe
Bahlis, Nizar Jacques
Facon, Thierry
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Usmani, Saad
BLOOD, 2022, 140 : 10150 - 10153
[28] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
Kumar, S. K.
Moreau, P.
Bahlis, N.
Facon, T.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Raje, N.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Wang, G.
Krevvata, M.
Carson, R.
Borgsten, F.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 183 - 184
[29] Overall survival and progression-free survival by treatment duration with Daratumumab plus Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
Moreau, Philippe
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph R.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Tromp, Brenda
Delioukina, Maria
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S1 - S1
[30] AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Dimopoulos, M. A.
Grosicki, S.
Jedrzejczak, W.
Nahi, H.
Gruber, A.
Hansson, M.
Byrne, C.
Labotka, R.
Teng, Z.
Yang, H.
Grzasko, N.
Kumar, S.
HAEMATOLOGICA, 2017, 102 : 111 - 111

← 1 2 3 4 5 →